4 Healthcare Stock Stories for Tuesday Investment Wellness

Amarin Corporation (NASDAQ:AMRN): Current price $7.24

On Monday, Amarin said that additional data from its previously reported MARINE and ANCHOR Phase 3 clinical trial results of Vascepa (icosapent ethyl) related to the effect of Vascepa on apolipoprotein C-III. It is thought that The lipoprotein Apo C-III inhibits the clearance of triglycerides from the blood. Persons who do not produce Apo C-III have lower levels of triglycerides and lower instances of cardiovascular disease. Amarin is a biopharmaceutical firm focused on the commercialization and development of therapeutics to improve cardiovascular health.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AMRN

Gilead Sciences (NASDAQ:GILD): Current price $48.41

Gilead said that it has submitted a New Drug Application to the FDA for approval of sofosbuvir, a once-daily oral nucleotide analogue for treating chronic hepatitis C virus infection. The data submitted in this NDA support the use of sofosbuvir and ribavirin as an all-oral therapy for patients suffering from genotype 2 and 3 HCV Infection, and for sofosbuvir in combination with RBV and pegylated interferon for treatment-naïve patients with genotype 1, 4, 5 and 6 HCV infection.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GILD

Johnson & Johnson (NYSE:JNJ): Current price $81.52

Analyst Michael Weinstein says J.P.Morgan downgraded shares from Overweight to Neutral, but concurrently elevated the price target from $77 to $83. Weinstein said in his report that “last June, J&J was trading at a 5 percent discount to the sum-of-its-parts; now the shares trade at an 8 percent premium after a 30 percent run (and $54 billion in increased market cap). As good as Pharma and Consumer Staples stocks have been, J&J of late has been even better; and while fundamentals have improved at J&J, at $82 we think this is much more reflected in the name.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JNJ

Bristol-Myers Squibb Company (NYSE:BMY): Current price $40.86

The firm announced on Sunday it has appointed Francis Cuss as its next chief scientific officer after Elliott Sigal retires as head of research and development on June 30. Sigal has led Bristol’s research efforts since 2004 and has overseen the approval of 14 new medicines on his tenure, will also resign from the board. Bristol had not previously announced Sigal’s retirement plans. Cuss will take over the top scientific post on July 1. He joined Bristol-Myers in 2003 after 14 years working at Schering-Plough and three with British drugmaker GlaxoSmithKline.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BMY

Investing Insights: Will CVS Continue to Skyrocket?